MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

NCT06969781 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DEVICE: MWA
DRUG: TKI

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]